Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
Earnings Data
Report Date
Nov 30, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.42Last Year’s EPS
-0.98Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Biofrontera's earnings call reflects a successful first half of 2025 marked by record sales, strategic independence, and strong financial backing, despite increased net losses and legal costs. The overall sentiment is buoyed by positive operational changes and future growth prospects.Company Guidance
Record-Breaking Sales of Ameluz
For the first time, Biofrontera sold over 50,000 tubes of Ameluz in the first half of 2025, showcasing a successful strategic shift and customer segmentation.
Increased Lamp Installations
40 RhodoLED XL lamps were placed in physician offices during the first half of 2025, signaling strong future growth with over 700 lamps now in use.
Total Revenue Growth
Total revenues for the second quarter of 2025 were $9.0 million, a 15.4% increase from $7.8 million in the second quarter of 2024.
Improved Gross Margins
Cost of revenues decreased by 42% compared to the same period in 2024, due to a shift to a royalty model and improved operational efficiencies.
Successful Restructuring with Biofrontera AG
Biofrontera Inc. became independent from Biofrontera AG, with a new agreement reducing the Ameluz transfer price and improving financial terms.
Strong Financial Support
Biofrontera secured an $11 million investment to support restructuring efforts and future growth.
Pipeline Progress
Completed enrollment in the Phase III study for actinic keratosis on the trunk, neck, and extremities, and Phase III trial for superficial basal cell carcinoma, with a promising outlook for FDA submissions.
Patent Extension
Received patent approval extending Ameluz's protection through December 2043, supporting long-term investment recovery and profitability.
BFRI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BFRI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 13, 2025 | $0.95 | $0.97 | +2.11% |
May 15, 2025 | $0.70 | $0.65 | -7.14% |
Mar 21, 2025 | $1.03 | $0.86 | -16.50% |
Nov 13, 2024 | $0.83 | $0.70 | -15.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biofrontera (BFRI) report earnings?
Biofrontera (BFRI) is schdueled to report earning on Nov 30, 2025, Before Open (Confirmed).
What is Biofrontera (BFRI) earnings time?
Biofrontera (BFRI) earnings time is at Nov 30, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BFRI EPS forecast?
BFRI EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.